46 related articles for article (PubMed ID: 1840100)
21. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
22. Molecular and clinical heterogeneity of adult GM2 gangliosidosis.
Navon R
Dev Neurosci; 1991; 13(4-5):295-8. PubMed ID: 1840100
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
Suzuki K; Vanier MT
Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
[TBL] [Abstract][Full Text] [Related]
24. [Recent advances in molecular genetics of GM2 gangliosidosis].
Wakamatsu N
Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
[TBL] [Abstract][Full Text] [Related]
25. The clinical aspects of adult hexosaminidase deficiencies.
Federico A; Palmeri S; Malandrini A; Fabrizi G; Mondelli M; Guazzi GC
Dev Neurosci; 1991; 13(4-5):280-7. PubMed ID: 1840098
[TBL] [Abstract][Full Text] [Related]
26. [Tay-Sachs disease].
Tanaka A
Nihon Rinsho; 1993 Sep; 51(9):2281-5. PubMed ID: 8411703
[TBL] [Abstract][Full Text] [Related]
27. The beta-hexosaminidase deficiency disorders: development of a clinical paradigm in the mouse.
Tifft CJ; Proia RL
Ann Med; 1997 Dec; 29(6):557-61. PubMed ID: 9562524
[TBL] [Abstract][Full Text] [Related]
28. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene.
Myerowitz R
Hum Mutat; 1997; 9(3):195-208. PubMed ID: 9090523
[TBL] [Abstract][Full Text] [Related]
29. The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis.
Mahuran DJ
Biochim Biophys Acta; 1991 Feb; 1096(2):87-94. PubMed ID: 1825792
[No Abstract] [Full Text] [Related]
30. Biochemical consequences of mutations causing the GM2 gangliosidoses.
Mahuran DJ
Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
[TBL] [Abstract][Full Text] [Related]
31. Late-onset GM2 gangliosidosis and other hexosaminidase mutations among Jews.
Navon R
Adv Genet; 2001; 44():185-97. PubMed ID: 11596983
[No Abstract] [Full Text] [Related]
32. [Spinal muscular atrophy: a hexosaminidase A deficiency phenotype].
Kawanami T; Kato T
Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):379-81. PubMed ID: 10434678
[No Abstract] [Full Text] [Related]
33. Biology and potential strategies for the treatment of GM2 gangliosidoses.
Chavany C; Jendoubi M
Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
[TBL] [Abstract][Full Text] [Related]
34. [Biochemical, molecular and social aspects of carrier screening for Tay-Sachs disease].
Peleg L; Gazit E; Goldman B; Akstein E
Harefuah; 1995 Dec; 129(11):475-80. PubMed ID: 8846957
[No Abstract] [Full Text] [Related]
35. Naturally occurring mutations in GM2 gangliosidosis: a compendium.
Triggs-Raine B; Mahuran DJ; Gravel RA
Adv Genet; 2001; 44():199-224. PubMed ID: 11596984
[No Abstract] [Full Text] [Related]
36. Biochemical characterization of the GM2 gangliosidosis B1 variant.
Tutor JC
Braz J Med Biol Res; 2004 Jun; 37(6):777-83. PubMed ID: 15264019
[TBL] [Abstract][Full Text] [Related]
37. GM2 gangliosidosis with a motor neuron disease phenotype: clinical heterogeneity of hexosaminidase deficiency disease.
Federico A
Adv Exp Med Biol; 1987; 209():19-23. PubMed ID: 2953177
[No Abstract] [Full Text] [Related]
38. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.
Leal AF; Benincore-Flórez E; Solano-Galarza D; Garzón Jaramillo RG; Echeverri-Peña OY; Suarez DA; Alméciga-Díaz CJ; Espejo-Mojica AJ
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867370
[TBL] [Abstract][Full Text] [Related]
39. Neuropathology of late onset gangliosidoses. A review.
Suzuki K
Dev Neurosci; 1991; 13(4-5):205-10. PubMed ID: 1817025
[TBL] [Abstract][Full Text] [Related]
40. The gangliosidoses.
Volk BW; Adachi M; Schneck L
Hum Pathol; 1975 Sep; 6(5):555-69. PubMed ID: 170187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
